Skip to content

Development and preliminary validation of a novel diagnostic probe for urothelial carcinoma

Development and preliminary validation of a novel diagnostic probe for urothelial carcinoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200067094
Enrollment
Unknown
Registered
2022-12-27
Start date
2022-12-29
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urothelial carcinoma

Interventions

Gold Standard:Pathological findings of urothelial carcinoma
Index test:New diagnostic probe

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) The patient was clinically diagnosed as urothelial carcinoma, which was in line with the indication of total cystectomy. Specifically, 1) high-risk non muscle invasive bladder cancer; 2) Recurrent non muscular invasive bladder cancer; 3) Multiple and extensive non muscular invasive bladder cancer could not be completely resected by electric resection; 3) No distant metastasis occurred in myometrial invasive bladder cancer (t2-t4a). (2) Men or women over the age of 18 years old can do it without clear surgical contraindications. (3) The patient has the intention of surgery and plans to undergo total cystectomy in the urology department of our hospital. (4) Through preoperative communication, the patients and their families indicated that they were fully informed of the condition and the choice of treatment plan and signed the informed consent and informed choice notification. Note: the above standards are met at the same time.

Exclusion criteria

Exclusion criteria: (1) Patients who refused surgical treatment or explicitly refused to participate in this clinical study; (2) Patients with decompensation of cardiopulmonary basic diseases, severe bleeding tendency diseases and other contraindications to anesthesia or surgery. Note: it is sufficient to meet any of the above standards.

Design outcomes

Primary

MeasureTime frame
fluorescence intensity;

Countries

China

Contacts

Public ContactXuesong Li

Peking University First Hospital

pineneedle@sina.com13631308453

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026